Back to Search
Start Over
Effect of Endoscopic Bronchial Ultrasound on Outcomes for Stage I Non-Small-Cell Lung Cancer Patients Receiving Hypofractionated Radiotherapy.
- Source :
-
Clinical lung cancer [Clin Lung Cancer] 2018 Mar; Vol. 19 (2), pp. e227-e233. Date of Electronic Publication: 2017 Aug 31. - Publication Year :
- 2018
-
Abstract
- Background: In this study we sought to determine if staging endoscopic bronchial ultrasound (EBUS) improves outcomes in stage I non-small-cell lung cancer (NSCLC) patients who received hypofractionated radiation therapy (HFRT).<br />Patients and Methods: Patients with stage I NSCLC treated with HFRT from 2008 to 2015 were retrospectively identified from 3 affiliated institutions. All patients underwent positron emission tomography/computed tomography staging and a subset of patients received pretreatment EBUS. Patients with and without pre-radiation therapy EBUS were compared for baseline characteristics. The log rank test was used to compare Kaplan-Meier estimates. Univariate analysis (UVA) and multivariable analysis (MVA) were used to analyze the effect of factors on disease-free survival (DFS) and overall survival (OS).<br />Results: Ninety-two patients met study criteria. Median follow-up for the entire cohort was 21 months. Two-year DFS and OS were 63% and 81%, respectively. Two-year freedom from local, regional, and distant failure were 93%, 87%, and 87%, respectively. Thirty-seven of 92 patients (40%) received pretreatment EBUS. There were no statistically significant differences in 2-year freedom from regional failure rates, DFS, or OS for EBUS-staged versus non-EBUS-staged patients. On UVA, smaller tumor size (P = .03) and higher performance status (P = .05) were associated with improved OS. On MVA, tumor size retained significance for improved OS (hazard ratio [HR], 0.44; 95% confidence interval [CI], 0.19-0.97; P = .04) and higher performance status showed a trend toward improved OS (HR, 0.51; 95% CI, 0.23-1.11; P = .09).<br />Conclusion: In this retrospective series, we did not detect a difference in regional failure or survival outcomes among stage I NSCLC patients who received invasive staging with EBUS before HFRT.<br /> (Copyright © 2017 Elsevier Inc. All rights reserved.)
- Subjects :
- Aged
Aged, 80 and over
Bronchi pathology
Carcinoma, Non-Small-Cell Lung mortality
Carcinoma, Non-Small-Cell Lung radiotherapy
Cohort Studies
Female
Follow-Up Studies
Humans
Lung Neoplasms mortality
Lung Neoplasms radiotherapy
Male
Middle Aged
Neoplasm Recurrence, Local
Neoplasm Staging
Retrospective Studies
Survival Analysis
Treatment Outcome
Bronchi diagnostic imaging
Carcinoma, Non-Small-Cell Lung diagnosis
Endosonography methods
Lung Neoplasms diagnosis
Radiation Dose Hypofractionation
Subjects
Details
- Language :
- English
- ISSN :
- 1938-0690
- Volume :
- 19
- Issue :
- 2
- Database :
- MEDLINE
- Journal :
- Clinical lung cancer
- Publication Type :
- Academic Journal
- Accession number :
- 28939097
- Full Text :
- https://doi.org/10.1016/j.cllc.2017.08.003